B-cell Acute Lymphoblastic Leukemia (B-ALL) Clinical Trials

10 recruiting

Frequently Asked Questions

Common questions about B-cell Acute Lymphoblastic Leukemia (B-ALL) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 1Phase 2

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca83 enrolled26 locationsNCT07109219
Recruiting

A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab

B-cell Acute Lymphoblastic LeukemiaB-Cell Lymphoblastic LeukemiaB-cell Acute Lymphoblastic Leukemia (B-ALL)+5 more
Arkansas Children's Hospital Research Institute300 enrolled2 locationsNCT07422337
Recruiting
Phase 1Phase 2

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca163 enrolled79 locationsNCT06137118
Recruiting
Early Phase 1

JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)

B-cell Acute Lymphoblastic Leukemia (B-ALL)
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China20 enrolled1 locationNCT06514768
Recruiting
Phase 1Phase 2

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

B-cell Acute Lymphoblastic Leukemia (B-ALL)B Lineage Lymphoblastic Lymphoma
Stephan Grupp MD PhD89 enrolled1 locationNCT05480449
Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

Chronic Lymphocytic Leukemia (CLL)B-cell Acute Lymphoblastic Leukemia (B-ALL)Autoimmune Hemolytic Anemia, AIHA+1 more
Grit Biotechnology28 enrolled2 locationsNCT07205315
Recruiting

CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions

B-cell Acute Lymphoblastic Leukemia (B-ALL)
St. Jude Children's Research Hospital80 enrolled1 locationNCT07048535
Recruiting
Phase 2Phase 3

Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol

Childhood Leukemia, Acute LymphoblasticB-cell Acute Lymphoblastic Leukemia (B-ALL)Acute Lymphoblastic Leukemia ALL
Institute of Hematology & Blood Diseases Hospital, China3,000 enrolled27 locationsNCT06882057
Recruiting
Not Applicable

Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)

B-ALLB-cell Acute Lymphoblastic Leukemia (B-ALL)Philadelphia Chromosome Negative
University of Chicago20 enrolled1 locationNCT06785324
Recruiting
Phase 2Phase 3

Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol

Childhood Leukemia, Acute LymphoblasticB-cell Acute Lymphoblastic Leukemia (B-ALL)Acute Lymphoblastic Leukemia ALL
Institute of Hematology & Blood Diseases Hospital, China1,800 enrolled26 locationsNCT06764238